Clinical Trial Update: A Study of SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression. [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial evaluating SHR-A1811 in combination with capecitabine for unresectable or metastatic breast cancer with low HER2 expression (Phase 1/Phase 2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• SHR-A1811

Snippet

Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Conditions: Breast Cancer | Phase 1, Phase 2 | Status: UNKNOWN